Liver Transplantation in Patients With Cardiac Disease

2017 ◽  
Vol 22 (2) ◽  
pp. 111-121 ◽  
Author(s):  
Christopher L. Wray
Keyword(s):  
Cardiovascular Disease ◽  
Liver Transplantation ◽  
Perioperative Period ◽  
Cardiovascular Complications ◽  
Adverse Outcomes ◽  
Treatment Modalities ◽  
Cardiac Complications ◽  
Major Step ◽  
Cardiac Evaluation ◽  
The Impact

Liver transplantation (LT) is a unique surgical procedure that has major hemodynamic and cardiovascular implications. Recently, there has been significant interest focused on cardiovascular issues that affect LT patients in all phases of the perioperative period. The preoperative cardiac evaluation is a major step in the selection of LT candidates. LT candidates are aging in concordance with the general population; cardiovascular disease and their risk factors are highly associated with older age. Underlying cardiovascular disease has the potential to affect outcomes in LT patients and has a major impact on candidate selection. The prolonged hemodynamic and metabolic instability during LT may contribute to adverse outcomes, especially in patients with underlying cardiovascular disease. Cardiovascular events are not unusual during LT; transplant anesthesiologists must be prepared for these events. Advanced cardiovascular monitoring techniques and treatment modalities are now routinely used during LT. Postoperative cardiovascular complications are common in both the early and late posttransplant periods. The impact of cardiac complications on posttransplant mortality is well recognized. Emerging knowledge regarding cardiovascular disease in LT patients and its impact on posttransplant outcomes will have an important role in guiding the future perioperative management of LT patients.

scholarly journals S1137 The Impact of Electrocardiogram Parameters on Cardiovascular Complications at Time of Liver Transplantation

2021 ◽  
Vol 116 (1) ◽  
pp. S533-S534
Author(s):  
Taseen Syed ◽  
Gurukripa Kowlgi ◽  
Anna Tomdio ◽  
Steve Shen ◽  
Samarth Patel ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Cardiovascular Complications ◽  
The Impact

scholarly journals Incidence of and Risk Factors for Perioperative Cardiovascular Complications in Spine Surgery

F1000Research ◽  
2022 ◽  
Vol 11 ◽  
pp. 15
Author(s):  
Haruthai Chotisukarat ◽  
Phuping Akavipat ◽  
Pathomporn Suchartwatnachai ◽  
Pimwan Sookplung ◽  
Jatuporn Eiamcharoenwit
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Congestive Heart Failure ◽  
Spine Surgery ◽  
Perioperative Period ◽  
Cardiovascular Complications ◽  
Cardiac Complications ◽  
Scoliosis Surgery ◽  
Number Of Patients ◽  
Risk Patients

Background: An increasing number of patients are opting for spine surgery despite the associated risk of cardiovascular complications. The evidence regarding the incidence and risk factors of cardiovascular complications in spine surgery is insufficient. Therefore, we aimed to determine the incidence and risk factors for cardiovascular complications that occur perioperatively in spine surgery. Methods: This retrospective study included all patients who underwent spine surgery between January 2018 and December 2019 at a single center. Demographic, clinical, and operative data were collected from electronic medical records. The incidence of perioperative cardiac complications was determined. Univariate and multivariate analyses were performed to identify risk factors for the development of perioperative cardiovascular complications in the participants. Results: Of the 1,002 eligible patients enrolled in the study, six developed cardiac complications. Acute myocardial infarction, cardiac arrest, and congestive heart failure occurred in one, two, and three patients, respectively. Risk factors for cardiovascular complications included scoliosis surgery (relative risk: RR, 18.61; 95% confidence interval (CI): 1.346-257.35) and a history of congestive heart failure (RR, 120.97; 95% CI: 2.12-6898.80). Conclusion: The incidence of perioperative cardiovascular complications in patients who underwent spine surgery was 0.6%. High-risk patients should be closely monitored optimally managed throughout the perioperative period.

The impact of different medical complications on the feasibility of removing the feeding tube from infants with dysphagia

2021 ◽  
Vol 14 (3) ◽  
pp. 371-377
Author(s):  
Hikari Fukatsu ◽  
Kanji Nohara ◽  
Nobukazu Tanaka ◽  
Nami Fujii ◽  
Takayoshi Sakai
Keyword(s):  
Tube Feeding ◽  
Feeding Tube ◽  
Cardiovascular Complications ◽  
Oral Feeding ◽  
Medical Complications ◽  
Cardiac Complications ◽  
Medical Complication ◽  
Feeding Tubes ◽  
Tube Removal ◽  
The Impact

PURPOSE: This study examined whether certain medical complications influence the feasibility of tube removal. METHODS: 42 subjects with dysphagia who were under the age of 2.5 years were nourished entirely through feeding tubes. Additionally, they were judged to have no aspiration. The following data about the infants were collected through a retroactive survey: age at which oral feeding training commenced, gender, and whether certain medical complications (cardiovascular, respiratory, digestive, neurological, or oral) had been present at birth. The data were analyzed to determine which type of medical complication affected the likelihood of removing the feeding tube from the infant at 3 years of age. RESULTS: Of the five medical complications examined, cardiovascular complications significantly affected the feasibility of tube removal (p = 0.049). CONCLUSION: Pediatric dysphagia patients with cardiac complications, compared to those with other complications, may take longer to transition off tube feeding.

The Utility of Anti-Inflammatory Agents in Cardiovascular Disease

2018 ◽  
Vol 23 (6) ◽  
pp. 483-493 ◽  
Author(s):  
Santhosh J. Kottoor ◽  
Rohit R. Arora
Keyword(s):  
Cardiovascular Disease ◽  
Cardiovascular Diseases ◽  
New England ◽  
Treatment Options ◽  
Current Treatment ◽  
Adverse Outcomes ◽  
Treatment Modalities ◽  
Clear Understanding ◽  
Acute Phase Reactants ◽  
Increased Risk

Approximately 40% of heart attack survivors remain at increased risk of recurrent cardiovascular events, despite the current treatment options showing that atherothrombosis is not exclusively a disorder of lipoprotein aggregation in the arterial wall. Clinical and experimental data suggest that inflammation plays an important role in atherothrombosis independent of the cholesterol level. Acute-phase reactants, such as C-reactive protein, increase in patients with coronary artery disease and are known to predict adverse outcomes in such patients. The recent CANTOS trial published in The New England Journal of Medicine provides evidence that interleukin-1β along with other cytokines play central roles in the inflammatory reaction that drives the interleukin-6 signaling pathway and have profound effects on cardiovascular outcomes. Several other ongoing studies are focused on multiple immune mediators involved in this process to support the inflammatory hypothesis of cardiovascular diseases. These new classes of drugs could represent the biggest breakthrough in cardiovascular medicine, which could have the greatest impact on cardiovascular mortality since the advent of statins. The drug canakinumab has shown promise in lowering atherosclerosis, and other drugs, such as colchicine and methotrexate, are gaining interest and are being investigated in multiple ongoing trials. A major concern is the affordability of these drugs, as most cardiovascular diseases are noted among people of lower socioeconomic statuses. The LoDoCo trial showed some benefits of colchicine, and whether this old drug can be marketed with a new label for cardiovascular disease remains in question. Therefore, a clear understanding of the different inflammatory pathways involved in atherosclerosis is needed to help develop more effective treatment modalities that will benefit humankind.

Molecular advances in cardiac and cardiovascular disease

Perfusion ◽  
1999 ◽  
Vol 14 (2) ◽  
pp. 89-99 ◽  
Author(s):  
Annette Basile-Borgia ◽  
John H Abel ◽  
Haleh Mahloogi
Keyword(s):  
Cardiovascular Disease ◽  
Gene Transfer ◽  
Vascular Diseases ◽  
Treatment Modalities ◽  
Cardiovascular Disorders ◽  
New Techniques ◽  
Phenotypic Changes ◽  
The Future ◽  
Molecular Therapies ◽  
The Impact

Recent advances in the field of molecular biology have led to a better understanding of the pathological mechanisms of cardiovascular disease. The impact of these findings will shape the future of treatment modalities for cardiovascular disorders. Postulated targets and biological rationale of new techniques are being developed in a race towards molecular therapies for vascular diseases. Whether it is modulation of transmembrane cell receptors or phenotypic changes via vectors that mediate gene transfer, there is no doubt that molecular strategies will be an integral part of the future. Here we examine past and recent perspectives, describe directions and challenges in cardiac and cardiovascular areas of research, and discuss relevance to the field of cardiovascular perfusion.

scholarly journals Cardiovascular Complications of COVID-19 Infection

2021 ◽  
Vol 34 (9) ◽  
pp. 608
Author(s):  
Maria Ana Trêpa ◽  
António Hipólito Reis ◽  
Mario Oliveira
Keyword(s):  
Cardiac Arrhythmias ◽  
Myocardial Injury ◽  
Clinical Presentation ◽  
Cardiac Injury ◽  
Cardiovascular Complications ◽  
Adverse Outcomes ◽  
Cardiac Complications ◽  
Usual Practice ◽  
Coronary Syndromes ◽  
Worse Prognosis

Introduction: Reports of cardiovascular complications related to the COVID-19 infection have been frequent.Methods: Narrative review for relevant articles on the topic. The classic cardiovascular risk factors, like age, obesity, diabetes, and hypertension are associated with adverse outcomes in COVID-19 patients. Cardiovascular complications can have a diverse clinical presentation including silent myocardial injury, acute coronary syndromes, thromboembolism, cardiac arrhythmias, and heart failure. There are multiple mechanisms of cardiac injury that are not mutually exclusive. The approach to diagnosis and management should be carried out according to usual practice, while considering the particularities of COVID-19 infection.Conclusion: The interaction between SARS-CoV-2 and the heart is complex and is manifested in multiple ways. Regardless of the clinical presentation, cardiac complications convey a worse prognosis. Patients should be actively monitored and treated accordingly.

scholarly journals CARDIOVASCULAR DISEASE IN COVID-19 PATIENTS. PART 1.

2020 ◽  
Vol 18 (6) ◽  
pp. 643-647
Author(s):  
V. S. Holyshko ◽  
◽  
V. A. Snezhitskiy ◽  
N. V. Matsiyeuskaya ◽  
◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Cardiovascular System ◽  
Critically Ill Patients ◽  
Medical Problem ◽  
Adverse Outcomes ◽  
The Other ◽  
Cardiovascular Pathology ◽  
Cardiovascular Damage ◽  
The One ◽  
The Impact

The COVID-19 pandemic caused by SARS-CoV-2 is the greatest medical problem of our time. The presence of concomitant cardiovascular pathology in a patient predisposes to a severe course and the formation of adverse outcomes of COVID-19. It is currently known that SARS-CoV-2 infection leads, on the one hand, to exacerbation and decompensation of the patient's cardiovascular disease, on the other hand, it is the origin of acute cardiovascular pathology. Understanding the impact of COVID-19 on the cardiovascular system is essential for providing comprehensive care to critically ill patients. In this review, we summarize the rapidly changing data on cardiovascular damage associated with COVID-19.

scholarly journals COVID-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors

2021 ◽  
pp. 1-10
Author(s):  
Manuel Alfredo Podestà ◽  
Federica Valli ◽  
Andrea Galassi ◽  
Matthias A. Cassia ◽  
Paola Ciceri ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Cardiovascular Events ◽  
Experimental Studies ◽  
Cardiovascular Complications ◽  
High Risk Population ◽  
High Prevalence ◽  
The Impact

Cardiovascular disease is a frequent complication and the most common cause of death in patients with CKD. Despite landmark medical advancements, mortality due to cardiovascular disease is still 20 times higher in CKD patients than in the general population, which is mainly due to the high prevalence of risk factors in this group. Indeed, in addition to traditional cardiovascular risk factors, CKD patients are exposed to nontraditional ones, which include metabolic, hormonal, and inflammatory alterations. The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has brought novel challenges for both cardiologists and nephrologists alike. Emerging evidence indicates that coronavirus disease 2019 (COVID-19) increases the risk of cardiovascular events and that several aspects of the disease may synergize with pre-existing cardiovascular risk factors in CKD patients. A better understanding of these mechanisms is pivotal for the prevention and treatment of cardiovascular events in this context, and we believe that additional clinical and experimental studies are needed to improve cardiovascular outcomes in CKD patients with COVID-19. In this review, we provide a summary of traditional and nontraditional cardiovascular risk factors in CKD patients, discussing their interaction with SARS-CoV-2 infection and focusing on CO­VID-19-related cardiovascular complications that may severely affect short- and long-term outcomes in this high-risk population.

scholarly journals Review of Cardiac Involvement in Multisystem Inflammatory Syndrome in Children

Circulation ◽  
2021 ◽  
Vol 143 (1) ◽  
pp. 78-88
Author(s):  
Tarek Alsaied ◽  
Adriana H. Tremoulet ◽  
Jane C. Burns ◽  
Arwa Saidi ◽  
Audrey Dionne ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Acute Infection ◽  
Gastrointestinal Symptoms ◽  
The United States ◽  
Cardiovascular Complications ◽  
Cardiac Complications ◽  
Published Data ◽  
Control And Prevention ◽  
Cardiac Evaluation ◽  
Inflammatory Syndrome

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with substantial cardiovascular implications. Although infection with SARS-CoV-2 is usually mild in children, some children later develop a severe inflammatory disease that can have manifestations similar to toxic shock syndrome or Kawasaki disease. This syndrome has been defined by the US Centers for Disease Control and Prevention as multisystem inflammatory syndrome in children. Although the prevalence is unknown, >600 cases have been reported in the literature. Multisystem inflammatory syndrome in children appears to be more common in Black and Hispanic children in the United States. Multisystem inflammatory syndrome in children typically occurs a few weeks after acute infection and the putative etiology is a dysregulated inflammatory response to SARS-CoV-2 infection. Persistent fever and gastrointestinal symptoms are the most common symptoms. Cardiac manifestations are common, including ventricular dysfunction, coronary artery dilation and aneurysms, arrhythmia, and conduction abnormalities. Severe cases can present as vasodilatory or cardiogenic shock requiring fluid resuscitation, inotropic support, and in the most severe cases, mechanical ventilation and extracorporeal membrane oxygenation. Empirical treatments have aimed at reversing the inflammatory response using immunomodulatory medications. Intravenous immunoglobulin, steroids, and other immunomodulatory agents have been used frequently. Most patients recover within days to a couple of weeks and mortality is rare, although the medium- and long-term sequelae, particularly cardiovascular complications, are not yet known. This review describes the published data on multisystem inflammatory syndrome in children, focusing on cardiac complications, and provides clinical considerations for cardiac evaluation and follow-up.

Sign in / Sign up

Export Citation Format

Share Document